StockData
Cingulate Inc. logo

Cingulate Inc. (CING) stock

CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.72+0.97 (+25.87%)

Close on Nov 17, 2026Market cap $68.64MP/E –Yield –

Cingulate free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cingulate's free cash flow for the twelve months ending Jun 30, 2026 was -$20.94M. For fiscal 2025 it was -$17.41M. The highest annual figure on record is -$7.21M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.41M–
FY2024Dec 31, 2024-$18.66M–
FY2023Dec 31, 2023-$15.26M–
FY2022Dec 31, 2022-$16.04M–
FY2021Dec 31, 2021-$11.25M–
FY2020Dec 31, 2020-$7.21M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.97M–
Q1 FY2026Mar 31, 2026-$6.97M–
Q4 FY2025Dec 31, 2025-$3.75M–
Q3 FY2025Sep 30, 2025-$4.24M–
Q4 FY2024Dec 31, 2024-$4.28M–
Q1 FY2024Mar 31, 2024-$8.83M–
Q4 FY2023Dec 31, 2023-$2.75M–
Q3 FY2023Sep 30, 2023-$4.29M–
Q2 FY2023Jun 30, 2023-$4.60M–
Q1 FY2023Mar 31, 2023-$3.61M–
Q4 FY2022Dec 31, 2022-$4.35M–
Q3 FY2022Sep 30, 2022-$3.40M–
Q2 FY2022Jun 30, 2022-$4.41M–
Q1 FY2022Mar 31, 2022-$3.87M–
Q4 FY2021Dec 31, 2021-$5.33M–
Q3 FY2021Sep 30, 2021-$2.60M–
Q2 FY2021Jun 30, 2021-$1.57M–
Q1 FY2021Mar 31, 2021-$1.74M–

More Cingulate figures

See a number that looks wrong?